The Pharmacodynamics of Alpha and Beta Blockade
Author:
Prichard B. N. C.
Publisher
Vieweg+Teubner Verlag
Reference54 articles.
1. Agabiti-Rosei, E., Alicandri, C. L., Beschi, M., Castellano, M., Fabriello, R., Montini, E., Muiesan, M. L., Romanelli, G. and Muiesan, G., 1982: The acute and chronic hypotensive effect of labetalol and the relationship with pretreatment plasma noradrenaline levels. British Journal of Clinical Pharmacology 13, (Suppl. 1), 87S - 92S. 2. Balasubramanian, V., Mann, S., Millar-Craig, M. W. and Raftery, E. B., 1979: Effect of labetalol in hypertension during exercise and postural changes. British Journal of Clinical Pharmacology 8 (Suppl. 2), 95S - 100S. 3. Beilen, L. J. and Juel-Jensen, B. E., 1972: Alpha and beta adrenergic blockade in hypertension. Lancet 1, 979–982. 4. Blakeley, A. G. H. and Summers, R. J., 1977: The effects of labetalol (AH 5158) on adrenergic transmission in the cat spleen. British Journal of Pharmacology 59, 643–660. 5. Boakes, A. J., Knight, E. J. and Prichard, B. N. C., 1971: Preliminary studies of the pharmacological effects of 5-{1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]-ethyl}salicylamide (AH 5158) in in man. Clinical Science 40, 18P - 19 P.
|
|